From GlobeNewswire: 2025-02-19 16:05:00

iBio, Inc. announced that its common stock has been approved for listing on the Nasdaq Capital Market, with trading expected to begin on Mar 4, 2025, under the symbol “IBIO.” The move aims to improve visibility, enhance trading liquidity, and attract institutional investors. CEO Martin Brenner expressed excitement about joining the Nasdaq community and leveraging AI to develop precision antibody therapies for various diseases, including cancer and obesity. iBio’s innovative approach combines 3D modeling with advanced drug discovery platforms to address unmet medical needs and accelerate precision medicine. For more information, visit www.ibioinc.com.

The Company’s forward-looking statements highlight the benefits of transitioning to Nasdaq, including increased visibility, enhanced liquidity, and exposure to institutional investors. While iBio believes in the reasonableness of these statements, they caution against placing undue reliance on them due to potential risks and uncertainties that could affect actual results. These include the Company’s ability to execute its growth strategy, obtain regulatory approvals, and successfully commercialize its product candidates for cardiometabolic diseases and oncology. Financial filings with the SEC provide additional information on these risks.



Read more at GlobeNewswire: iBio to Begin Trading on the Nasdaq Stock Exchange